Elpida™ Included in Essential Drugs List for HIV-1 in Russia

- Viriom's Elsulfavirine (Elpida™)-based regimens for treatment of HIV-1 infection will be available to all patients and physicians in both regionally and federally funded programs in Russia

SAN DIEGO, Sept. 5, 2018 -- Viriom, Inc., a San Diego-based biotech, announces that on Sept 4th, 2018, the commission of the Russian Ministry of Health included Elpida™, Viriom's once-daily 20 mg oral formulation of its innovative drug elsulfavirine, in Russia's List of Vital and Essential Drugs (VED).

Inclusion of Elpida™, Viriom's best in class non-nucleoside reverse transcriptase inhibitor (NNRTI), provides full access to the drug for all patients and physicians for HIV treatment and prophylaxis, and is chiefly funded under the Russian Government's State Strategy and Implementation Plan on HIV until 2020 and beyond.

The decision to list Elpida™ in VED was based on evaluation of Elpida's medical and pharmacoeconomic merit, and paves the way for quick adoption of Elpida™ as the preferred NNRTI standard of care by the regulatory and physician community, with strong support from patient organizations.

NNRTIs block HIV by inhibiting a key enzyme in virus replication. During preclinical and clinical development, elsulfavirine demonstrated a higher genetic barrier to development of resistance-conferring viral mutations, high efficacy, superior safety and tolerability over other antiretroviral medicines; and clinical pharmacology advantageous for development of less frequent drug administration.

Viriom, Inc. obtained its first Russian marketing approval for Elpida™ in June 2017 for treatment of HIV-1 in combination with other antiretroviral medicines. Viriom is launching Elpida™ in several developing markets, expecting to treat over 8000 HIV patients in 2017-2018. Elpida™ and elsulfavirine based fixed dose combinations and elsulfavirine once weekly dosing regimen are undergoing market registration and development in several countries including Thailand, countries of the Eurasian Economic Union and the USA.

About Viriom: Viriom focuses on the treatment, prophylaxis, and eradication of infectious diseases globally. Viriom is developing and commercializing the most innovative and affordable solutions to radically expand global access to antiviral treatments. Viriom's broad, proprietary, and partnered pipeline covers therapeutic, prophylactic, and curative medicines for HIV and viral hepatitis. Learn more at www.viriom.com.

Media Contact:

Ronald DemuthCFO, Viriom

+1(858)-724-0581

rdemuth@viriom.com

Safe Harbor Statement

This document may contain forward-looking statements. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements. We believe that it is important to publicly communicate future expectations. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, the uncertainties associated with product development, the market for our products, the risks associated with dependence upon key personnel and the need for additional financing. We do not assume any obligation to update forward-looking statements as circumstances change. The information in this document is not targeted at the residents of any particular country or jurisdiction and is not intended for distribution to, or use by, any person in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. The future expectations, estimations, anticipated events, results, milestones, events, operating and financial information contained in the company's financial projections and all other areas of this document are for illustrative purposes only and are based upon hypothetical assumptions and events over which the company has only partial or no control. All information about future events (projections) were developed by the company's management and are based upon a variety of assumptions with or without benefit of an operating history. The projections are included solely to provide information concerning the company's estimates of future operating results based on these assumptions and, although the company believes that these assumptions are reasonable, they may be incomplete or incorrect, and unanticipated events and circumstances may occur. Actual results will vary from the projections, and these variations may be material and adverse. The projections should be read in conjunction with the assumptions upon which the projections are based. No representation or warranty of any kind is or can be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from our projections or the assumptions underlying them.

Viriom to Present its Innovative Medicines for Treatment and Prophylaxis of HIV and Announce the Plan for Accessing Chinese Market

Beijing, September 03 -- Viriom Inc. (Viriom) will present its innovative medicines for treatment and prophylaxis of HIV and announce the plan for accessing Chinese market at the international China BioMed Innovation and Investment Conference (CBIIC). The CBIIC will be held in Suzhou on September 18-20.

Since 2016, the CBIIC gathers vast audiences of medical professionals and investment companies; in 2018, it will bring more than 3,500 participants, 700 pharmaceutical companies, 500 financial institutions, including experts in the pharmaceutical industry, officials, media representatives, to discuss solutions for Chinese Healthcare and Pharma industry. The 2018 conference will establish more than 10 parallel sessions in the Suzhou Industrial Park, and promises to be "the most influential event in the world for pharmaceutical innovation and investment in Asia." The organization team includes a board of investor groups, China Pharmaceutical Innovation and Research Development Association (PhiRDA), China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee, various research centers. This is the perfect platform for Viriom global team to meet current and future regional partners, share an international experience and, bring more development and product insight about Viriom’s HIV line of products to healthcare community and its patients.

One of the leading products of Viriom Inc. is elsulfavirine (aka ESV, brand name Elpida® a once daily 20mg capsules, best in class non-nucleoside reverse transcriptase inhibitor to block HIV replication), Viriom licensed Elida from Roche in 2009. Based on the positive clinical result from a 48-week, multi-center clinical trial, followed by 96-100 week pivotal study, Viriom Inc. launched and continues to launch Elpida in several developing markets expecting to treat over 8000 HIV patients in 2017-2018.  Elpida, elsulfavirine based fixed dose combinations and elsulfavirine once weekly dosing regimen are undergoing market registration and development in several countries including Thailand and USA. According to the new rules for innovative drugs established by CFDA, Elpida has a potential to obtain market authorization in China via fast track.

 

About Viriom

Viriom Inc. is a commercial and late-stage development biotech company researching, manufacturing and distributing novel and affordable therapies and prophylaxis against life-threatening infections such as HIV and HBV. Viriom holds a an exclusive worldwide license  from F. Hoffmann-La Roche for elsulfavirine to treat HIV1 infection, and long acting injectable    VM1500A drug candidate for treatment and prevention of HIV infection in high-risk patient populations. Viriom is also developing proprietary dual and triple fixed dose regimens; VM3500 a long acting integrase strand transfer inhibitor drug candidate for treatment of HIV1 infection and VM2500 a potentially best in class pro-drug tenofovir  for treatment of HIV and HBV infections. Viriom established its China subsidiary in Beijing in June 2018 and started to register its products in Chinese FDA.

For more information, please visit https://www.viriom.com/home-cn/

 

Contact:  

info@viriom.com

PR manager Xi Ailing

Viriom to Present Pre-Clinical Studies with Elsulfavirine/VM1500A Long-Acting Parenteral and Oral Formulations at the International Conference on HIV/AIDS, STDs & STIs 2018

SAN DIEGO, April 16, 2018 /PRNewswire/ -- Viriom Inc. today announced that its study report "Elsulfavirine/VM1500A Long-Acting Parenteral and Oral Formulations for Treatment and Prevention of HIV-1 Infections" will be presented by Dr. Vadim Bichko, Viriom's Chief Scientific Officer, at the International Conference on HIV/AIDS, STDs & STIs on April 24th, 2018 in Valencia, Spain. The study evaluates new options for treatment and prevention of HIV/AIDS that would allow for infrequent dosing, thus facilitating patients' compliance and likely improving long-term treatment outcomes.